Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents: 12-month results from the prospective multicentre FOCUS registry

Feng Zhang; Junbo Ge; Juying Qian; Lei Ge; Jun Zhou; Yuejin Yang; Fang Chen; Xiaoling Zhu; Shuzheng Lv; Zhizhong Li; Haichang Wang; Yin Liu; Yawei Xu; Zhanquan Li; Huigen Jin; Weiyi Fang; Xuchen Zhou; Lijun Jing; Yundai Chen; Changyong Zhou; Zhexun Lian; Yi An; Yongjian Yang; Zhixiong Zhong; Zuyi Yuan; Xiaofei Sun; Guotai Sheng; Zhenming Yan; Ren Ke Yi; Jian An; Bin Liu; Zesheng Xu; Xiaoqun Pu; Yongwen Qin; Shuangying Feng; Guosheng Fu; Chunlin Lai; Bo Yu; Tiemin Jiang; Lefeng Wang; Weiming Wang; Jianjun Peng; Hui Li; Wenyue Pang; Biao Xu; Haiming Shi; Meng Wei; Changqian Wang; Ying Zhu; Ningfu Wang; Shaoliang Chen; Qiang Fu; Shian Huang; Keng Wu; Yutian Tong; Zheng Zhang; Ge Zhang; Hesong Zeng; Hong Jiang; Wenwei Liu; Guoying Zhu; Ping Li; Xuekun Zhang; Zhimin Du; Yingfeng Liu; Weimin Li; Ling Liu; Ben He; Wei Gao; Dalin Jia; Jinchuan Yan; Shaorong Liu; Chuanhuan Zhang; Yimin Fang; Zhigang Tao; Jifu Li; He Huang; Xingui Guo; Xinghua Zhang; Tongbao Liu; Lianqun Cui; Jianming Xiao; Lianglong Chen; Jinfa Jiang; Chenzhi Lu; Xueqi Li; Peng Qu; Yan Wang; Honghua Ye; Jingtian Li; Yuqing Hou; Qiutang Zeng; Yuanze Jin; Dongju Jiang; Kanghua Ma; Dadong Zhang; Suwatchai Pornratanarangsi; Muhamad Munawar; Teguh Santoso

doi:10.4244/EIJV8I8A138

Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents: 12-month results from the prospective multicentre FOCUS registry

Feng Zhang, Junbo Ge, Juying Qian, Lei Ge, Jun Zhou, Yuejin Yang, Fang Chen, Xiaoling Zhu, Shuzheng Lv, Zhizhong Li, Haichang Wang, Yin Liu, Yawei Xu, Zhanquan Li, Huigen Jin, Weiyi Fang, Xuchen Zhou, Lijun Jing, Yundai Chen, Changyong ZhouZhexun Lian, Yi An, Yongjian Yang, Zhixiong Zhong, Zuyi Yuan, Xiaofei Sun, Guotai Sheng, Zhenming Yan, Ren Ke Yi, Jian An, Bin Liu, Zesheng Xu, Xiaoqun Pu, Yongwen Qin, Shuangying Feng, Guosheng Fu, Chunlin Lai, Bo Yu, Tiemin Jiang, Lefeng Wang, Weiming Wang, Jianjun Peng, Hui Li, Wenyue Pang, Biao Xu, Haiming Shi, Meng Wei, Changqian Wang, Ying Zhu, Ningfu Wang, Shaoliang Chen, Qiang Fu, Shian Huang, Keng Wu, Yutian Tong, Zheng Zhang, Ge Zhang, Hesong Zeng, Hong Jiang, Wenwei Liu, Guoying Zhu, Ping Li, Xuekun Zhang, Zhimin Du, Yingfeng Liu, Weimin Li, Ling Liu, Ben He, Wei Gao, Dalin Jia, Jinchuan Yan, Shaorong Liu, Chuanhuan Zhang, Yimin Fang, Zhigang Tao, Jifu Li, He Huang, Xingui Guo, Xinghua Zhang, Tongbao Liu, Lianqun Cui, Jianming Xiao, Lianglong Chen, Jinfa Jiang, Chenzhi Lu, Xueqi Li, Peng Qu, Yan Wang, Honghua Ye, Jingtian Li, Yuqing Hou, Qiutang Zeng, Yuanze Jin, Dongju Jiang, Kanghua Ma, Dadong Zhang, Suwatchai Pornratanarangsi, Muhamad Munawar, Teguh Santoso

Department of Cardiology and Vascular Medicine

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Aims: The FOCUS registry is a prospective, multicentre, web-based programme designed to collect clinical outcome data from real-world patients receiving the second-generation cobalt-chromium sirolimus-eluting stent (CoCr-SES). Methods and results: From March 2009 to February 2010, a total of 5,084 patients from 83 centres who were eligible to receive CoCr-SES were enrolled in the FOCUS registry. The primary endpoint was 12-month major adverse cardiac events (MACE, defined as the composite of cardiac death, myocardial infarction [MI], and target vessel revascularisation [TVR]). One-year data were available for 5,013 (98.6%) of the 5,084 patients enrolled. The primary endpoint occurred in 174 (3.47%) of 5,013 patients, consisting of 43 (0.86%) cardiac deaths, 132 (2.63%) MI, and 46 (0.92%) TVR. According to the Academic Research Consortium definition, definite and probable stent thrombosis (ST) occurred in 0.52% (26/5,013) of patients, including 19 cases of early ST and 7 of late ST. The 12-month MACE rates were 3.73% and 2.60% for extended-use and standard-use patients, respectively (p=0.065). Conclusions: The second-generation CoCr-SES was associated with low rates of 12-month MACE and ST in a broad spectrum of patients, thereby confirming the clinical safety and efficacy of this stent in a real-world setting.

Original language	English
Pages (from-to)	896-903
Number of pages	8
Journal	EuroIntervention
Volume	8
Issue number	8
DOIs	https://doi.org/10.4244/EIJV8I8A138
Publication status	Published - Dec 2012

Keywords

Cobalt-chromium stent
Coronary artery disease
Sirolimus-eluting stent

Access to Document

10.4244/EIJV8I8A138

Cite this

Zhang, F., Ge, J., Qian, J., Ge, L., Zhou, J., Yang, Y., Chen, F., Zhu, X., Lv, S., Li, Z., Wang, H., Liu, Y., Xu, Y., Li, Z., Jin, H., Fang, W., Zhou, X., Jing, L., Chen, Y., ... Santoso, T. (2012). Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents: 12-month results from the prospective multicentre FOCUS registry. EuroIntervention, 8(8), 896-903. https://doi.org/10.4244/EIJV8I8A138

@article{b47fa7fc9ca44d6b96494b2623d6e5a8,

title = "Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents: 12-month results from the prospective multicentre FOCUS registry",

abstract = "Aims: The FOCUS registry is a prospective, multicentre, web-based programme designed to collect clinical outcome data from real-world patients receiving the second-generation cobalt-chromium sirolimus-eluting stent (CoCr-SES). Methods and results: From March 2009 to February 2010, a total of 5,084 patients from 83 centres who were eligible to receive CoCr-SES were enrolled in the FOCUS registry. The primary endpoint was 12-month major adverse cardiac events (MACE, defined as the composite of cardiac death, myocardial infarction [MI], and target vessel revascularisation [TVR]). One-year data were available for 5,013 (98.6%) of the 5,084 patients enrolled. The primary endpoint occurred in 174 (3.47%) of 5,013 patients, consisting of 43 (0.86%) cardiac deaths, 132 (2.63%) MI, and 46 (0.92%) TVR. According to the Academic Research Consortium definition, definite and probable stent thrombosis (ST) occurred in 0.52% (26/5,013) of patients, including 19 cases of early ST and 7 of late ST. The 12-month MACE rates were 3.73% and 2.60% for extended-use and standard-use patients, respectively (p=0.065). Conclusions: The second-generation CoCr-SES was associated with low rates of 12-month MACE and ST in a broad spectrum of patients, thereby confirming the clinical safety and efficacy of this stent in a real-world setting.",

keywords = "Cobalt-chromium stent, Coronary artery disease, Sirolimus-eluting stent",

author = "Feng Zhang and Junbo Ge and Juying Qian and Lei Ge and Jun Zhou and Yuejin Yang and Fang Chen and Xiaoling Zhu and Shuzheng Lv and Zhizhong Li and Haichang Wang and Yin Liu and Yawei Xu and Zhanquan Li and Huigen Jin and Weiyi Fang and Xuchen Zhou and Lijun Jing and Yundai Chen and Changyong Zhou and Zhexun Lian and Yi An and Yongjian Yang and Zhixiong Zhong and Zuyi Yuan and Xiaofei Sun and Guotai Sheng and Zhenming Yan and Yi, {Ren Ke} and Jian An and Bin Liu and Zesheng Xu and Xiaoqun Pu and Yongwen Qin and Shuangying Feng and Guosheng Fu and Chunlin Lai and Bo Yu and Tiemin Jiang and Lefeng Wang and Weiming Wang and Jianjun Peng and Hui Li and Wenyue Pang and Biao Xu and Haiming Shi and Meng Wei and Changqian Wang and Ying Zhu and Ningfu Wang and Shaoliang Chen and Qiang Fu and Shian Huang and Keng Wu and Yutian Tong and Zheng Zhang and Ge Zhang and Hesong Zeng and Hong Jiang and Wenwei Liu and Guoying Zhu and Ping Li and Xuekun Zhang and Zhimin Du and Yingfeng Liu and Weimin Li and Ling Liu and Ben He and Wei Gao and Dalin Jia and Jinchuan Yan and Shaorong Liu and Chuanhuan Zhang and Yimin Fang and Zhigang Tao and Jifu Li and He Huang and Xingui Guo and Xinghua Zhang and Tongbao Liu and Lianqun Cui and Jianming Xiao and Lianglong Chen and Jinfa Jiang and Chenzhi Lu and Xueqi Li and Peng Qu and Yan Wang and Honghua Ye and Jingtian Li and Yuqing Hou and Qiutang Zeng and Yuanze Jin and Dongju Jiang and Kanghua Ma and Dadong Zhang and Suwatchai Pornratanarangsi and Muhamad Munawar and Teguh Santoso",

year = "2012",

month = dec,

doi = "10.4244/EIJV8I8A138",

language = "English",

volume = "8",

pages = "896--903",

journal = "EuroIntervention",

issn = "1774-024X",

publisher = "EuroPCR",

number = "8",

}

Zhang, F, Ge, J, Qian, J, Ge, L, Zhou, J, Yang, Y, Chen, F, Zhu, X, Lv, S, Li, Z, Wang, H, Liu, Y, Xu, Y, Li, Z, Jin, H, Fang, W, Zhou, X, Jing, L, Chen, Y, Zhou, C, Lian, Z, An, Y, Yang, Y, Zhong, Z, Yuan, Z, Sun, X, Sheng, G, Yan, Z, Yi, RK, An, J, Liu, B, Xu, Z, Pu, X, Qin, Y, Feng, S, Fu, G, Lai, C, Yu, B, Jiang, T, Wang, L, Wang, W, Peng, J, Li, H, Pang, W, Xu, B, Shi, H, Wei, M, Wang, C, Zhu, Y, Wang, N, Chen, S, Fu, Q, Huang, S, Wu, K, Tong, Y, Zhang, Z, Zhang, G, Zeng, H, Jiang, H, Liu, W, Zhu, G, Li, P, Zhang, X, Du, Z, Liu, Y, Li, W, Liu, L, He, B, Gao, W, Jia, D, Yan, J, Liu, S, Zhang, C, Fang, Y, Tao, Z, Li, J, Huang, H, Guo, X, Zhang, X, Liu, T, Cui, L, Xiao, J, Chen, L, Jiang, J, Lu, C, Li, X, Qu, P, Wang, Y, Ye, H, Li, J, Hou, Y, Zeng, Q, Jin, Y, Jiang, D, Ma, K, Zhang, D, Pornratanarangsi, S, Munawar, M & Santoso, T 2012, 'Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents: 12-month results from the prospective multicentre FOCUS registry', EuroIntervention, vol. 8, no. 8, pp. 896-903. https://doi.org/10.4244/EIJV8I8A138

TY - JOUR

T1 - Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents

T2 - 12-month results from the prospective multicentre FOCUS registry

AU - Zhang, Feng

AU - Ge, Junbo

AU - Qian, Juying

AU - Ge, Lei

AU - Zhou, Jun

AU - Yang, Yuejin

AU - Chen, Fang

AU - Zhu, Xiaoling

AU - Lv, Shuzheng

AU - Li, Zhizhong

AU - Wang, Haichang

AU - Liu, Yin

AU - Xu, Yawei

AU - Li, Zhanquan

AU - Jin, Huigen

AU - Fang, Weiyi

AU - Zhou, Xuchen

AU - Jing, Lijun

AU - Chen, Yundai

AU - Zhou, Changyong

AU - Lian, Zhexun

AU - An, Yi

AU - Yang, Yongjian

AU - Zhong, Zhixiong

AU - Yuan, Zuyi

AU - Sun, Xiaofei

AU - Sheng, Guotai

AU - Yan, Zhenming

AU - Yi, Ren Ke

AU - An, Jian

AU - Liu, Bin

AU - Xu, Zesheng

AU - Pu, Xiaoqun

AU - Qin, Yongwen

AU - Feng, Shuangying

AU - Fu, Guosheng

AU - Lai, Chunlin

AU - Yu, Bo

AU - Jiang, Tiemin

AU - Wang, Lefeng

AU - Wang, Weiming

AU - Peng, Jianjun

AU - Li, Hui

AU - Pang, Wenyue

AU - Xu, Biao

AU - Shi, Haiming

AU - Wei, Meng

AU - Wang, Changqian

AU - Zhu, Ying

AU - Wang, Ningfu

AU - Chen, Shaoliang

AU - Fu, Qiang

AU - Huang, Shian

AU - Wu, Keng

AU - Tong, Yutian

AU - Zhang, Zheng

AU - Zhang, Ge

AU - Zeng, Hesong

AU - Jiang, Hong

AU - Liu, Wenwei

AU - Zhu, Guoying

AU - Li, Ping

AU - Zhang, Xuekun

AU - Du, Zhimin

AU - Liu, Yingfeng

AU - Li, Weimin

AU - Liu, Ling

AU - He, Ben

AU - Gao, Wei

AU - Jia, Dalin

AU - Yan, Jinchuan

AU - Liu, Shaorong

AU - Zhang, Chuanhuan

AU - Fang, Yimin

AU - Tao, Zhigang

AU - Li, Jifu

AU - Huang, He

AU - Guo, Xingui

AU - Zhang, Xinghua

AU - Liu, Tongbao

AU - Cui, Lianqun

AU - Xiao, Jianming

AU - Chen, Lianglong

AU - Jiang, Jinfa

AU - Lu, Chenzhi

AU - Li, Xueqi

AU - Qu, Peng

AU - Wang, Yan

AU - Ye, Honghua

AU - Li, Jingtian

AU - Hou, Yuqing

AU - Zeng, Qiutang

AU - Jin, Yuanze

AU - Jiang, Dongju

AU - Ma, Kanghua

AU - Zhang, Dadong

AU - Pornratanarangsi, Suwatchai

AU - Munawar, Muhamad

AU - Santoso, Teguh

PY - 2012/12

Y1 - 2012/12

N2 - Aims: The FOCUS registry is a prospective, multicentre, web-based programme designed to collect clinical outcome data from real-world patients receiving the second-generation cobalt-chromium sirolimus-eluting stent (CoCr-SES). Methods and results: From March 2009 to February 2010, a total of 5,084 patients from 83 centres who were eligible to receive CoCr-SES were enrolled in the FOCUS registry. The primary endpoint was 12-month major adverse cardiac events (MACE, defined as the composite of cardiac death, myocardial infarction [MI], and target vessel revascularisation [TVR]). One-year data were available for 5,013 (98.6%) of the 5,084 patients enrolled. The primary endpoint occurred in 174 (3.47%) of 5,013 patients, consisting of 43 (0.86%) cardiac deaths, 132 (2.63%) MI, and 46 (0.92%) TVR. According to the Academic Research Consortium definition, definite and probable stent thrombosis (ST) occurred in 0.52% (26/5,013) of patients, including 19 cases of early ST and 7 of late ST. The 12-month MACE rates were 3.73% and 2.60% for extended-use and standard-use patients, respectively (p=0.065). Conclusions: The second-generation CoCr-SES was associated with low rates of 12-month MACE and ST in a broad spectrum of patients, thereby confirming the clinical safety and efficacy of this stent in a real-world setting.

AB - Aims: The FOCUS registry is a prospective, multicentre, web-based programme designed to collect clinical outcome data from real-world patients receiving the second-generation cobalt-chromium sirolimus-eluting stent (CoCr-SES). Methods and results: From March 2009 to February 2010, a total of 5,084 patients from 83 centres who were eligible to receive CoCr-SES were enrolled in the FOCUS registry. The primary endpoint was 12-month major adverse cardiac events (MACE, defined as the composite of cardiac death, myocardial infarction [MI], and target vessel revascularisation [TVR]). One-year data were available for 5,013 (98.6%) of the 5,084 patients enrolled. The primary endpoint occurred in 174 (3.47%) of 5,013 patients, consisting of 43 (0.86%) cardiac deaths, 132 (2.63%) MI, and 46 (0.92%) TVR. According to the Academic Research Consortium definition, definite and probable stent thrombosis (ST) occurred in 0.52% (26/5,013) of patients, including 19 cases of early ST and 7 of late ST. The 12-month MACE rates were 3.73% and 2.60% for extended-use and standard-use patients, respectively (p=0.065). Conclusions: The second-generation CoCr-SES was associated with low rates of 12-month MACE and ST in a broad spectrum of patients, thereby confirming the clinical safety and efficacy of this stent in a real-world setting.

KW - Cobalt-chromium stent

KW - Coronary artery disease

KW - Sirolimus-eluting stent

UR - http://www.scopus.com/inward/record.url?scp=84872142061&partnerID=8YFLogxK

U2 - 10.4244/EIJV8I8A138

DO - 10.4244/EIJV8I8A138

M3 - Article

C2 - 23253543

AN - SCOPUS:84872142061

VL - 8

SP - 896

EP - 903

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 8

ER -

Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents: 12-month results from the prospective multicentre FOCUS registry

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this